Navigation Links
Medivation Presents New Data on Dimebon's Novel Mechanism of Action
Date:12/9/2008

al mechanism of action may account for the clinical benefit observed in the Dimebon Alzheimer's and Huntington's disease clinical trials completed to date.

About Dimebon

Dimebon is an oral small molecule in development with Pfizer for Alzheimer's and Huntington's diseases. It is currently being evaluated in a second pivotal Phase 3 trial in Alzheimer's disease. Results from the first pivotal trial were published in the July 19, 2008, edition of The Lancet. A Phase 2 study in Huntington's disease was recently completed, and further development is planned in Huntington's disease.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation entered into a global agreement with Pfizer Inc to develop and commercialize Dimebon for the treatment of Alzheimer's and Huntington's diseases. With Pfizer, the Company is conducting a broad Dimebon clinical development program, including a pivotal and confirmatory Phase 3 trial, known as the CONNECTION study, in patients with mild-to-moderate Alzheimer's disease. The program also includes additional trials planned to begin next year in Alzheimer's disease, as well as further development of Dimebon in patients with mild-to-moderate Huntington's disease. In addition, a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer is ongoing. For more information, please visit us at http://www.medivation.com.

This press release contains forward-looking statements, including statements regarding the mechanism of action of Dimebon, the p
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Medivation Announces Participation in RBC Capital Markets 2008 Healthcare Conference
2. Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update
3. Medivation Announces Third Quarter 2008 Teleconference and Webcast on November 10, 2008
4. Medivation Announces Expiration of Hart-Scott-Rodino Waiting Period for Collaboration With Pfizer
5. Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients
6. Medivation Receives Corporate Achievement Award From Huntingtons Disease Society of America
7. Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Partnering Plans for Dimebon
8. Medivation Announces Participation in Upcoming Conferences
9. Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update
10. Medivation Announces Second Quarter 2008 Teleconference and Webcast on August 11, 2008
11. Medivation Announces Presentation at the BMO Capital Markets 2008 Focus on Healthcare Conference on August 5
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 This webinar ... on nonclinical and clinical safety assessment in biosimilars. ... guide a path for biosimilar drug development, however ... of biosimilarity with regards to quality, safety and ... of biosimilar drug development and registration, development strategies ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 ... an enhancement to its Online Web Portal for Life ... now have the ability to specify the subject matter ... nearly 50 life science sub-domains. This will help reduce ... and scientific fields, and decrease the likelihood of error. ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 ... – 11 p.m. , Location: Warrington Country Club, 1360 ... Hepatitis B Foundation, the only national nonprofit organization solely ... improving the quality of life for those affected worldwide, ... 11 at Warrington Country Club in Warrington, Pa. ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... initiated coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua ... and marketing proprietary products to serve the wound ... , In late 2012, Alliqua was restructured ... launched the company’s new strategy to become a ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... 8 Amsterdam,Molecular Therapeutics (Euronext: AMT), a leader in ... part of the newly created Next Biotech Index of,NYSE ... our company,for this index," said Ronald Lorijn, CEO of ... companies and will help investors to track,the performance of ...
... team is proud to announce,the USDA/CVB has granted ... as well as an autogenous bacterin license utilizing ... approval of our manufacturing facility and our oral ... significant milestone for,our Company, and we look forward ...
... of Molecular Vision today,announces that discussions with Acrongenomics ... ceased. Acrongenomics has been unable to,complete on the ... of,Molecular Vision believes that the best interests of ... a conclusion. Acrongenomics remains a,significant shareholder in Molecular ...
Cached Biology Technology:Amsterdam Molecular Therapeutics Part of Next Biotech Index 2PerOs obtains USDA Establishment and Product Licenses for it's oral vaccine formulations 2
(Date:4/14/2014)... are continuing to unravel the molecular changes that underlie ... infections. , When the bacterium Yersinia pestis enters the ... 100 percent fatal if untreated. The way in which ... kills people in a matter of days has largely ... demonstrating that the presence of a protein called the ...
(Date:4/14/2014)... the decision of whether to get a dog. ... can be even more challenging. Now, a University ... in families of children with autism and found, ... reported the benefits of dog ownership included companionship, ... learn responsibility. , "Children with autism spectrum disorders ...
(Date:4/14/2014)... Think of the pressure change you feel when an elevator ... how you,d feel if that elevator carried you all the ... the blink of an eye. , That,s similar to what ... near a dam. For some, the change in pressure is ... seriously injured. , In an article in the March issue ...
Breaking Biology News(10 mins):Plague alters cell death to kill host 2Dog ownership benefits families of children with autism, MU researcher finds 2Making dams safer for fish around the world 2Making dams safer for fish around the world 3Making dams safer for fish around the world 4Making dams safer for fish around the world 5
... of Insect Molecular Biology reports the detailed analyses ... pest, the Pea Aphid. The analyses are based on ... and is a major step in enhancing our understanding of ... significant plant pests. The sequencing of the Pea ...
... have calculated the energy and economic potential of urban ... slurry for generating electricity in Spain. These residues are ... friendly and, in the case of solid urban waste, ... has economic and environmental advantages. "It gives added value ...
... the launch of the first Meteosat in 1977, 33 ... given meteorologists the tools to improve weather forecasting, with ... improving with data from operational satellites, like Meteosat Second ... basis for numerical forecasts, making use of the world,s ...
Cached Biology News:Successful genome sequencing of pea aphid is a breakthrough for ecology and agricultural research 2Successful genome sequencing of pea aphid is a breakthrough for ecology and agricultural research 3Waste could generate up to 7 percent of electricity in Spain 2Waste could generate up to 7 percent of electricity in Spain 3
...
...
... designed to rapidly and reliably amplify ... patented APA Technology. APAgene provides hassle-free, ... competitive price. All necessary ingredients are ... Kit can be used for identifying ...
Protein YIPF6 (YIP1 family member 6). [Source:Uniprot/SWISSPROT;Acc:Q96EC8] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Biology Products: